TELA Bio, Inc. Common Stock (TELA) is a publicly traded Healthcare sector company. As of May 21, 2026, TELA trades at $0.91 with a market cap of $37.16M and a P/E ratio of -1.23. TELA moved +12.15% today. Year to date, TELA is -13.73%; over the trailing twelve months it is -28.65%. Its 52-week range spans $0.50 to $3.26. Analyst consensus is strong buy with an average price target of $2.00. Rallies surfaces TELA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TELA Bio Reports Q1 European Growth, Unveils U.S. Clinical Partnerships: TELA Bio Inc flagged accelerated European market growth during Q1 2026 driven by increased sales of its signature wound-healing implants. Management also outlined U.S. expansion plans involving clinical collaborations and facility capacity upgrades scheduled through 2026.
| Metric | Value |
|---|---|
| Price | $0.91 |
| Market Cap | $37.16M |
| P/E Ratio | -1.23 |
| EPS | $-0.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.26 |
| 52-Week Low | $0.50 |
| Volume | 48 |
| Avg Volume | 0 |
| Revenue (TTM) | $80.81M |
| Net Income | $-39.84M |
| Gross Margin | 67.25% |
4 analysts cover TELA: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.00.